Role of Fisetin in Selected Malignant Neoplasms in Women.

breast cancer cervical cancer fisetin flavonoids flavonols in vitro activity in vivo activity nanodelivery systems ovarian cancer

Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
05 Nov 2023
Historique:
received: 09 10 2023
revised: 31 10 2023
accepted: 03 11 2023
medline: 15 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

A promising therapeutic window and cost-effectiveness are just two of the potential advantages of using naturally derived drugs. Fisetin (3,3',4',7-tetrahydroxyflavone) is a natural flavonoid of the flavonol group, commonly found in fruit and vegetables. In recent years, fisetin has gained wide attention across the scientific community because of its broad spectrum of pharmacological properties, including cytotoxic activity against most abundant cancers. By stimulating or inhibiting selected molecular targets or biochemical processes, fisetin could affect the reduction of metastasis or cancer progression, which indicates its chemotherapeutic or chemopreventive role. In this review, we have summarized the results of studies on the anticancer effects of fisetin on selected female malignancies, both in in vitro and in vivo tests, i.e., breast, cervical, and ovarian cancer, published over the past two decades. Until now, no article dedicated exclusively to the action of fisetin on female malignancies has appeared. This review also describes a growing number of nanodelivery systems designed to improve the bioavailability and solubility of this natural compound. The reported low toxicity and activity of fisetin on cancer cells indicate its valuable potential, but large-scale clinical trials are urgently needed to assess real chemotherapeutic efficacy of this flavonoid.

Identifiants

pubmed: 37960338
pii: nu15214686
doi: 10.3390/nu15214686
pmc: PMC10648688
pii:
doi:

Substances chimiques

fisetin OO2ABO9578
Flavonols 0
Flavonoids 0
Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nutr Cancer. 2022;74(4):1163-1170
pubmed: 34278890
PLoS One. 2016 Mar 09;11(3):e0151134
pubmed: 26960146
Biomed Pharmacother. 2019 Aug;116:109004
pubmed: 31128404
Am J Clin Nutr. 2014 Nov;100(5):1344-51
pubmed: 25332332
J Invest Dermatol. 2011 Jun;131(6):1291-9
pubmed: 21346776
Front Pharmacol. 2018 Jul 31;9:772
pubmed: 30108501
Front Biosci (Elite Ed). 2017 Jan 1;9(1):67-75
pubmed: 27814590
Avicenna J Med Biotechnol. 2021 Oct-Dec;13(4):176-182
pubmed: 34900143
Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jul;49(4):551-555
pubmed: 30378308
Carcinogenesis. 2009 Feb;30(2):300-7
pubmed: 19037088
J Gynecol Oncol. 2022 Mar;33(2):e43
pubmed: 35245004
Nutrients. 2020 Feb 12;12(2):
pubmed: 32059369
Glob Med Genet. 2023 Aug 09;10(3):205-220
pubmed: 37565061
Biomolecules. 2019 May 06;9(5):
pubmed: 31064104
Biochem Biophys Res Commun. 2023 May 28;658:69-79
pubmed: 37027907
Eur J Pharmacol. 2015 Oct 5;764:79-86
pubmed: 26101063
Int J Pharm. 2022 Nov 25;628:122184
pubmed: 36252641
J Nanosci Nanotechnol. 2020 Oct 1;20(10):6040-6046
pubmed: 32384950
Int J Biol Macromol. 2019 Mar 15;125:700-710
pubmed: 30521927
J Epidemiol. 1998 Aug;8(3):168-75
pubmed: 9782673
Curr Med Chem Anticancer Agents. 2002 Nov;2(6):691-714
pubmed: 12678721
Life Sci. 2018 Feb 1;194:75-87
pubmed: 29225112
J Pharm Bioallied Sci. 2020 Nov;12(Suppl 2):S676-S680
pubmed: 33828360
Int J Oncol. 2020 Dec;57(6):1245-1261
pubmed: 33174058
Nutrition. 2020 Nov - Dec;79-80:110964
pubmed: 32877827
Tumour Biol. 2016 May;37(5):6987-96
pubmed: 26662956
Ginekol Pol. 2017;88(2):68-74
pubmed: 28326515
BMC Cancer. 2016 Feb 23;16:140
pubmed: 26906901
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell Death Dis. 2019 Feb 13;10(2):142
pubmed: 30760707
Pharmacogn Rev. 2014 Jul;8(16):122-46
pubmed: 25125885
Bioorg Med Chem. 2013 Jun 1;21(11):3348-55
pubmed: 23623675
Int J Mol Sci. 2022 Feb 01;23(3):
pubmed: 35163629
J Exp Clin Cancer Res. 2022 Aug 22;41(1):256
pubmed: 35989353
Int J Oncol. 2012 Feb;40(2):469-78
pubmed: 21922137
Molecules. 2021 Apr 02;26(7):
pubmed: 33918290
Food Chem Toxicol. 2018 Oct;120:528-535
pubmed: 30076913
J Ovarian Res. 2022 May 10;15(1):57
pubmed: 35538559
Antioxid Redox Signal. 2013 Jul 10;19(2):151-62
pubmed: 23121441
Biomed Pharmacother. 2018 Oct;106:1282-1291
pubmed: 30119198
Gene. 2021 Jun 30;787:145638
pubmed: 33848578
Front Chem. 2019 Oct 30;7:697
pubmed: 31750288
Cell Biol Int. 2023 Jan;47(1):98-109
pubmed: 36273436
World J Clin Oncol. 2016 Feb 10;7(1):54-86
pubmed: 26862491
Arch Toxicol. 2012 Feb;86(2):263-73
pubmed: 21964635
BMC Pharmacol Toxicol. 2021 Nov 2;22(1):68
pubmed: 34727985
BMC Cancer. 2020 Jan 2;20(1):4
pubmed: 31898540
PLoS One. 2013 Aug 05;8(8):e71983
pubmed: 23940799
J Nutr Sci. 2022 Sep 09;11:e74
pubmed: 36304817
Mol Nutr Food Res. 2008 May;52(5):507-26
pubmed: 18435439
Drug Deliv. 2017 Nov;24(1):224-232
pubmed: 28156161
Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Nov;47(6):830-836
pubmed: 28598107
Food Sci Nutr. 2020 Nov 25;9(1):3-16
pubmed: 33473265
Int J Mol Sci. 2020 Sep 07;21(18):
pubmed: 32906729
Expert Opin Drug Deliv. 2014 Jan;11(1):17-29
pubmed: 24294925
Nutrients. 2022 Jun 23;14(13):
pubmed: 35807785
J Nutr. 2000 Sep;130(9):2243-50
pubmed: 10958819
Curr Opin Biotechnol. 2020 Feb;61:153-159
pubmed: 31954357
Int J Cancer. 2010 Mar 1;126(5):1121-31
pubmed: 19685490
Ginekol Pol. 2022;93(8):670-674
pubmed: 35894484
Semin Cancer Biol. 2016 Oct;40-41:48-81
pubmed: 26853158
Pharmaceuticals (Basel). 2023 Jan 28;16(2):
pubmed: 37259344
J Cell Biochem. 2016 Aug;117(8):1913-25
pubmed: 26755433
Int J Biol Macromol. 2016 May;86:408-17
pubmed: 26820351
Int J Mol Sci. 2023 Sep 15;24(18):
pubmed: 37762460
Semin Cancer Biol. 2021 Feb;69:200-211
pubmed: 31374244
Pharmacol Res. 2021 Oct;172:105784
pubmed: 34302980
Chem Biol Interact. 2022 Apr 1;356:109869
pubmed: 35231453
BMC Complement Altern Med. 2018 Mar 15;18(1):91
pubmed: 29544480
Int J Mol Med. 2018 Aug;42(2):811-820
pubmed: 29749427
Nutrients. 2022 Feb 19;14(4):
pubmed: 35215535
Pharm Res. 2017 Feb;34(2):453-461
pubmed: 28004315
Artif Cells Nanomed Biotechnol. 2018;46(sup1):347-361
pubmed: 29334247
Breast Cancer Res Treat. 2010 Jul;122(1):45-53
pubmed: 19701705
J Biochem Mol Toxicol. 2019 Apr;33(4):e22268
pubmed: 30431692

Auteurs

Anna Markowska (A)

Department of Perinatology and Women's Health, Poznań University of Medical Sciences, 60-535 Poznań, Poland.

Michał Antoszczak (M)

Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, 61-614 Poznań, Poland.

Karol Kacprzak (K)

Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, 61-614 Poznań, Poland.

Janina Markowska (J)

Gynecological Oncology Center, Poznańska 58A, 60-850 Poznań, Poland.

Adam Huczyński (A)

Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, 61-614 Poznań, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH